Stryker Corporation $SYK Shares Sold by Phoenix Financial Ltd.

Phoenix Financial Ltd. lessened its holdings in Stryker Corporation (NYSE:SYK) by 14.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,393 shares of the medical technology company’s stock after selling 2,754 shares during the quarter. Phoenix Financial Ltd.’s holdings in Stryker were worth $5,783,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after purchasing an additional 133,892 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Stryker by 4.4% in the third quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock worth $851,457,000 after purchasing an additional 96,662 shares during the last quarter. Corient Private Wealth LLC raised its stake in shares of Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. Finally, Invesco Ltd. raised its stake in shares of Stryker by 4.5% in the third quarter. Invesco Ltd. now owns 1,864,918 shares of the medical technology company’s stock worth $689,404,000 after purchasing an additional 80,536 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Up 1.0%

Shares of SYK opened at $305.23 on Friday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The stock’s 50 day moving average is $331.20 and its two-hundred day moving average is $352.04. The firm has a market cap of $117.01 billion, a P/E ratio of 35.33, a PEG ratio of 1.90 and a beta of 0.80.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same period in the previous year, the business posted $2.84 earnings per share. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. UBS Group reduced their price objective on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Citigroup reduced their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a research report on Friday, May 1st. William Blair reiterated an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Stryker in a research report on Tuesday, January 27th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average target price of $395.48.

Insider Buying and Selling

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president directly owned 177 shares of the company’s stock, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.